Beijing-based cancer genomics solutions start-up Genetron Health has raised more than RMB400 million (US$61 million) in a series C round led by Zhongjin Kangrui Medical Industrial Fund. V Star Capital, a RMB investment vehicle funded by a team formerly at GGV Capital, and Shenshang Xingye Fund, a fund backed by the Shenzhen government, also participated in the round. Founded in 2013, Genetron Health focuses on precision medicine by providing cancer patients with molecular clinical services and professional cancer genetic risk assessment. Its products cover full-cycle …
Chinese Cancer Genomics Solutions Start-Up Genetron Health Raises $61M Series C appeared first on China Money Network.